Core Insights - Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program, highlighting a commitment to innovation and education in aesthetic medicine [1][4] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, focusing on various skin concerns including hyperpigmentation and premature aging [6] - Alpha Aesthetics Partners, founded in 2023, aims to advance the medical aesthetics industry through best-in-class support and clinical training, with a growing presence across 31 locations in 12 states [7] Program Details - The ALOHA Program will involve a structured, multi-site evaluation of Obagi's saypha MagIQ™ across Alpha's network, aiming to generate real-world evidence of the product's integration into clinical environments [2][3] - The program will collect standardized data to evaluate clinical performance and patient experience, with initial findings to be presented at the upcoming Alpha Summit [3] Product Information - Obagi's saypha MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Core Insights - Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program, highlighting a commitment to innovation and education in aesthetic medicine [1][4] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [6][10] - Alpha Aesthetics Partners, founded in 2023, aims to advance the medical aesthetics industry through best-in-class support and clinical training, with a growing presence across 31 locations in 12 states [7] Program Details - The ALOHA Program will involve a structured, multi-site evaluation of Obagi saypha MagIQ™ across Alpha's network, focusing on generating real-world evidence of the product's integration into clinical environments [2][3] - The program aims to assess both clinical performance and patient experience, with standardized data collection across participating practices, and initial findings to be presented at the upcoming Alpha Summit [3] Product Information - Obagi saypha ChIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, designed for natural-looking results and high performance [4]

Core Insights - ARC Health has secured a $182 million credit facility to refinance existing debt and support growth initiatives in the US [1][2] - The company aims to expand its presence and improve behavioral health services across important regions in the US [2] - Thurston Group, a private equity firm, supports ARC Health's growth strategy and the establishment of the new credit facility [3][4] Company Overview - Founded in 2021 and based in Cleveland, Ohio, ARC Health is an outpatient behavioral health provider [1] - The company operates 91 locations across 20 US states and employs over 1,300 clinicians [1] - ARC Health focuses on a data-driven, patient-centered model to achieve strong clinical and operational results [1] Growth Strategy - The new credit facility will provide ARC Health with the capital and flexibility needed for expansion and to support partner practices [2] - The acquisition of Mindsoother Therapy Center in January 2024 marks a significant step in ARC Health's growth journey [4]